Impact of molecular medicine on healthcare markets and strategies for success.
Improvements in the understanding of the molecular basis of disease are leading to profound market changes in healthcare. The authors of this perspective offer a comprehensive view of these market shifts and their relations to one another. Within the traditional healthcare system, these changes will include better cancer therapies, companion diagnostics and diagnostics that are not linked to single therapies. Business models that allow reimbursement for diagnostics to be based on clinical utility will prove successful. Increased quantitation of diagnostics will move point-of-care testing to the physician's office. The use of diagnostics for cost reduction will grow. Outside of the traditional health system, multiple new markets will emerge. The increasing quantitation of diagnostics reduces the need for interpretation by physicians, and new trusted sources of personal medical information will become prevalent. Patients will evolve into consumers as choice becomes available, and as entrepreneurial companies offer speed, convenience and a better customer experience around non-life-threatening diseases. Presymptomatic healthcare will be a particular area of growth, and will be especially attractive to consumers, who will find their traditional providers less accommodating than commercial suppliers. Consumer genomics companies and those who harness rapid technology improvements, quick clinics and home devices will be part of the growing new markets. Traditionally successful organizations will have difficulty responding to these changes. Organizations wishing to enter these growing fields will need aggressive and thoughtful strategies. Strategic planning, considering both vulnerabilities and opportunities, will need to take new forms and will require creativity and commitment.